Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Suspended 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Lymphoid 1

Conditions

Basal Cell Nevus Syndrome 3Carcinoma, Basal Cell 2Skin Neoplasms 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
gusacitinib × Dermatologic × Clear all
NCT04416516 2024-04-10

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Ascend Biopharmaceuticals Ltd

Phase 2 Completed
21 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT03208296 2023-02-06

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Ascend Biopharmaceuticals Ltd

Phase 1/2 Suspended
24 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02550678 2018-06-06

ASN-002-001

Ascend Biopharmaceuticals Ltd

Phase 1/2 Completed
16 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡